Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGC-11047 + gemcitabine
- Development stage
- Unknown
- Lead developer
- Cellgate
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CGC-11047 + gemcitabine is an investigational combination therapy for cancer. CGC-11047 is a second-generation polyamine analog of N1,N12-bisethylspermine, designed to inhibit cell proliferation and induce apoptosis in cancer cells by disrupting polyamine metabolism. It has demonstrated antitumor activity in preclinical models of lung, prostate, breast, and pancreatic cancers[6][7][8]. Gemcitabine is a nucleoside metabolic inhibitor (antimetabolite) that slows or stops the growth of cancer cells by interfering with DNA synthesis[1][4]. The combination has been studied in early-phase clinical trials to determine safety and maximum tolerated dose for various solid tumors[2][5].
- Brand names
- Gemzar
- Other names
- PG-11047PG11047PG 11047SL-11047SL11047SL 11047N1,N12-bisethylspermine (for CGC-11047)
02
Targets
Polyamine transporterDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on CGC-11047 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGC-11047 + gemcitabine.